Clinical features in patients with thyroid eye disease according to seropositivity for anti-acetylcholine receptor antibodies

Article information

Kosin Med J. 2026;41(3):250-255
Publication date (electronic) : 2026 July 6
doi : https://doi.org/10.7180/kmj.26.155
1Department of Ophthalmology, Pusan National University School of Medicine, Yangsan, Korea
2Biomedical Research Institute, Pusan National University Hospital, Busan, Korea
Corresponding Author: Heeyoung Choi, MD, PhD Department of Ophthalmology, Pusan National University School of Medicine, 179 Gudeok-ro, Seo-gu, Busan 49241, Korea Tel: 82-51-240-7342 Fax: 82-51-240-7320 E-mail: hychoi@pusan.ac.kr
Corresponding Author: Hyeshin Jeon, MD, PhD Department of Ophthalmology, Pusan National University School of Medicine, 179 Gudeok-ro, Seo-gu, Busan 49241, Korea Tel: 82-51-240-7342 Fax: 82-51-240-7320 E-mail: Hyeshin.jeon@gmail.com
**These authors contributed equally to this work as corresponding authors.
Received 2026 February 12; Revised 2026 May 4; Accepted 2026 June 11.

Abstract

Background

Thyroid eye disease (TED) is an autoimmune disorder associated with thyroid-related antigens. Myasthenia gravis (MG) is characterized by impaired neuromuscular transmission caused by an autoimmune response against acetylcholine receptors (AChRs). Because both diseases can present with ocular symptoms, their differential diagnosis can be challenging. This study compared the clinical features of patients with TED according to anti-AChR antibody seropositivity.

Methods

The medical records of patients diagnosed with TED who underwent anti-AChR antibody testing were retrospectively reviewed. Patients were classified into seropositive and seronegative groups according to anti-AChR antibody status. Clinical findings, including eyelid abnormalities, strabismus, and extraocular movement limitations, were compared between the groups.

Results

Seventy-four patients, including 31 male patients (41.9%), were included in the study, and the mean age was 49.9±16.7 years. Eight patients (10.8%) were classified into the seropositive group. Asymmetric exophthalmos was observed in 18 patients (27.7%). Eyelid abnormalities were identified in 37 patients (50.0%), including lid retraction in 22 (29.7%), lid lag in nine (12.2%), and ptosis in 15 (20.3%). Ptosis was more common in the seropositive group than in the seronegative group (50.0% vs. 16.7%; p=0.048). Strabismus was identified in 47 patients (63.5%); vertical strabismus was the most frequent type (51.4%), followed by combined vertical and horizontal strabismus (28.4%), exotropia (20.3%), and esotropia (20.3%). Exotropia (50.0% vs. 16.7%; p=0.048) and adduction limitation (50.0% vs. 10.6%; p=0.014) were significantly more frequent in the seropositive group.

Conclusions

Ptosis, exotropia, and adduction limitation were more frequent in patients with anti-AChR antibody-positive TED. The presence of these findings may warrant further evaluation for coexisting ocular MG.

Introduction

Thyroid eye disease (TED) is an autoimmune reaction caused by thyroid antigens, leading to the activation of T cells, which produce inflammatory cytokines. This results in the proliferation of fibroblasts within the orbital tissues, causing fibrosis and edema [1]. These nonspecific inflammatory responses commonly result in proptosis, eyelid edema, eyelid retraction, conjunctival hyperemia, and chemosis. Additionally, it can cause edema of the extraocular muscles, leading to ocular motility limitation and related restrictive strabismus [2,3].

Myasthenia gravis (MG) is a disorder characterized by impaired neuromuscular transmission due to an autoimmune response against acetylcholine receptors (AChR) at the neuromuscular junction [4]. Approximately 20% of cases are diagnosed as ocular MG, presenting with only ocular symptoms such as diplopia, strabismus, and ptosis, sharing clinical features with TED [5]. The anti-AChR antibody test is a simple and safe test with a high specificity of 97%–99% for diagnosing MG [6,7]. However, while 80%–90% of patients with generalized MG show seropositivity, only 40%–60% of those with ocular MG test positive [8-10].

The C-terminal region of thyroglobulin, one of the thyroid antigens, shares high molecular homology with acetylcholinesterase, which may lead to immunological cross-reactivity between anti-thyroglobulin and anti-AChR antibodies [11,12]. It has been reported that anti-AChR antibodies were detected in 8% of patients with TED without coexisting ocular MG [13]. Conversely, anti-thyroglobulin antibodies were detected in 13.4% of patients with MG who had no thyroid dysfunction [14]. Approximately 0.7%–1.3% of patients with TED are reported to have coexisting MG, and 3%–10% of patients with MG have accompanying TED [7,15]. When both diseases coexist, the sensitivity of the anti-AChR antibody test decreases further [10,16]. Since both diseases can cause ocular symptoms, such as diplopia and restricted ocular motility, differential diagnosis can be challenging in the absence of systemic symptoms. This study aimed to compare and analyze the clinical features in patients with TED according to the seropositivity for anti-AChR antibodies.

Methods

Ethical statements: This study was approved by the Institutional Review Board (IRB) of Pusan National University Hospital (IRB No. 2510-032-156). As this study retrospectively analyzed an anonymized dataset, a waiver of consent was obtained and approved.

The medical records of patients with TED who visited Pusan National University Hospital from January 2008 to May 2025 were retrospectively reviewed. Patients with a history of thyroid disease or thyroid dysfunction, along with clinical symptoms consistent with the VISA (vision, inflammation, strabismus, appearance) classification and the Clinical Activity Score, were diagnosed with TED. Testing for anti-AChR antibodies was conducted as part of the clinical examination, and the patients who did not undergo anti-AChR antibody test were excluded. The patients with a history of strabismus surgery, orbital decompression, or orbital fracture were also excluded.

All patients underwent a thorough ophthalmic examination. Strabismus was assessed using the Lancaster red-green test and the alternate prism cover test during fixation at 6 m. Version and duction were evaluated accordingly. The degree of ocular movement was quantified on a semiquantitative scale ranging from 0 (normal excursion) to –5 (no movement before reaching the midline). Grades –4 to –1 indicated residual motility at roughly 25% intervals of the normal range. This grading system was consistently applied throughout the study to describe the extent of ocular motility limitation [17]. Exophthalmos was evaluated using a Hertel exophthalmometer. Asymmetric exophthalmos was defined as a difference of 2 mm or more between both eyes [18]. Lid changes were evaluated in terms of ptosis, lid lag, and lid retraction. Ptosis was assessed using marginal reflex distances 1 (MRD1) and the levator function test. The patients with a MRD1 of less than 2.5 mm and a levator function of less than 8 mm were considered to have ptosis [19,20]. A MRD1 greater than 5 mm was considered as lid retraction [21]. Pseudoretraction was identified by eliminating the effect of Hering’s law through manual elevation of the ptotic lid [22].

Anti-AChR antibodies were quantitatively measured in patients’ serum using the radioimmunoassay (RIA) method. Patients were classified into a seropositive group or seronegative group based on whether their anti-AChR antibodies were ≥0.2 nmol/L [23].

All statistical analyses were performed using IBM SPSS ver. 29.0 (IBM Corp.). The chi-square test and Fisher exact test were used to analyze categorical variables. The Mann-Whitney U test was used to analyze continuous variables. A p-value <0.05 was considered statistically significant.

Results

A total of 74 (31 male) patients with TED were included; eight (10.8%) in the seropositive group and 66 (89.2%) in the seronegative group. The mean age was 49.9±16.7 years (range, 12 to 81 years). Nineteen patients (25.7%) had a history of smoking. Demographics were not different between the two groups.

Hyperthyroidism was the most common thyroid dysfunction in both groups. Thirty-eight patients (60.3%) exhibited positivity for thyroid stimulating hormone receptor antibody. Four patients (5.4%) had previously received steroid pulse therapy, and none had undergone radiation therapy because of TED (Table 1).

Characteristics of the patients

No significant differences in mean visual acuity or intraocular pressure were observed between the two groups. Asymmetric exophthalmos was observed in 18 patients (27.7%). Eyelid abnormalities were found in 37 patients (50.0%), including lid retraction in 22 (29.7%), lid lag in nine (12.2%), and ptosis in 15 (20.3%). Ptosis was more common in the seropositive group (50.0% vs. 16.7%; p=0.048). Although lid retraction and lid lag were not observed in the seropositive group, there were no statistically significant differences between the seropositive and seronegative group. There was also no significant difference in asymmetric exophthalmos between the two groups.

Strabismus was identified in 47 patients (63.5%), comprising vertical strabismus in 38 (51.4%), exotropia in 15 (20.3%), esotropia in 15 (20.3%), and combined strabismus in 21 (28.4%). In the seropositive group, seven patients (87.5%) had strabismus; vertical strabismus in six (75.0%), exotropia in four (50.0%), esotropia in one (12.5%), and combined strabismus in four (50.0%). In the seronegative group, 40 patients (60.6%) had strabismus; vertical strabismus in 32 (48.5%), exotropia in 11 (16.7%), esotropia in 14 (21.2%), and combined strabismus in 17 (25.8%). Vertical strabismus predominated in both groups. Esotropia was the least prevalent in the seropositive group, whereas exotropia was the least prevalent in the seronegative group. Exotropia was significantly more common in the seropositive group (p=0.048).

Supraduction limitation was the most common type of restriction of eyeball movement, observed in 37 patients (50.0%). Infraduction and adduction limitation were each present in 11 patients (14.9%), and abduction limitation in 18 (24.3%). While supraduction limitation was the most common type of ocular motility abnormality, adduction limitation was significantly more common in the seropositive group (p=0.014) (Table 2).

Comparison of clinical features between seropositive and seronegative groups

Six patients (8.1%) were diagnosed with MG following neurological consultation, based on findings from single-fiber electromyography, the ice test, and clinical response to pyridostigmine. Five (83.3%) were seropositive and one (16.7%) was seronegative. Exotropia was observed in four patients (66.7%), which was the most prevalent subtype of strabismus. Adduction limitation was identified in three patients (50.0%). Lid lag and lid retraction were not observed in any patients, whereas ptosis was documented in five patients (83.3%).

Discussion

We investigated the differences in clinical features of patients with TED based on the seropositivity for anti-AChR antibodies. In the seropositive group, ptosis was frequently observed, while lid retraction and lid lag were not observed. Both groups exhibited vertical strabismus and supraduction limitation most commonly. Some patients exhibited limited ocular movements in both adduction and abduction, resulting in variable horizontal strabismic deviation. Exotropia and adduction limitation were more common in the seropositive group.

Ptosis is commonly observed in ocular MG due to involvement of the levator palpebrae superioris muscle. Patients with ocular MG often present with asymmetric ptosis and are often accompanied by diplopia [24]. In contrast, true ptosis is rare in TED; however, it may occur secondarily due to eyelid swelling. Furthermore, pseudoptosis in the contralateral upper eyelid may result from unilateral upper eyelid retraction [7]. In this study, ptosis was more commonly observed in the seropositive group. Claytor and Li [7] suggested that the presence of true eyelid ptosis in patients with TED should raise suspicion for coexisting ocular MG, in line with our study [25].

Abnormal ocular motility and related ocular misalignment may occur in both TED and MG; however, these manifestations arise from distinct underlying mechanisms. TED induces edema of the extraocular muscles, resulting in limited relaxation of the muscles involved. The inferior and medial rectus muscles are commonly affected, while lateral rectus is rarely involved [26]. MG causes muscle weakness due to an autoimmune reaction at the neuromuscular junction. While it can affect all extraocular muscles, it frequently involves the medial rectus muscle, resulting in limitation of adduction and exotropia [4]. Accordingly, patients with TED commonly present with limitations of supraduction and abduction, along with vertical strabismus and esotropia. Patients with ocular MG often present with adduction limitation and exotropia [7,27]. In this study, adduction limitation and exotropia were more commonly observed in the seropositive group.

TED, which is caused by autoimmune response to thyroid antigens, is associated with various other autoimmune diseases. Previous studies have reported that TED can, albeit rarely, be accompanied by MG [7,15]. TED and ocular MG can present with similar ophthalmic symptoms, making diagnosis challenging when both coexist. The presence of orbicularis oculi muscle weakness, ptosis, and fluctuations of symptoms, deterioration of symptoms despite appropriate treatment in the patients with TED should raise suspicion for concurrent MG [12,28,29]. Since exotropia is exceedingly rare in patients with TED without ocular MG, the presence of exotropia may also indicate a possible coexistence of ocular MG [7,30]. In this study, patients with coexisting MG commonly exhibited exotropia and adduction limitation, and ptosis was frequently observed without other eyelid abnormalities. These findings indicate that patients with coexisting MG showed clinical features comparable to those of the seropositive group.

The AChR antibody test is typically performed using RIA method. Although this test demonstrates a high specificity of 97%–99% for ocular MG, its sensitivity is relatively low, ranging from 40% to 60% [6,8,9]. The prevalence of antibody is reported to be even lower in patients with coexisting autoimmune thyroid disease [16]. Therefore, ocular MG cannot be excluded in patients who test negative for AChR antibodies. In cases with clinical features suggestive of ocular MG, such as adduction limitation, or ptosis with diurnal variation, single-fiber electromyography—which is considered the most sensitive test for ocular MG—can be useful for diagnosis [31].

This study has several limitations. First, the retrospective design may have introduced inconsistencies in data collection. Second, the number of subjects in seropositive group was relatively small (n=8), which may have led to potential overestimation of effect sizes, limiting the robustness and reproducibility of the findings. The marked imbalance in sample size between the seropositive and seronegative group may have compromised the statistical power of the analysis. Accordingly, results demonstrating borderline statistical significance (p=0.048) should be interpreted with caution, as they may be sensitive to minor variations in the data, raising the possibility of a typeⅠerror. Third, since the clinical features were evaluated at the initial visit, long-term changes in clinical course could not be assessed. Therefore, further prospective studies with larger sample sizes are warranted to clarify the long-term clinical characteristics and treatment outcomes in patients with coexisting TED and ocular MG.

In conclusion, in patients with TED who present with eyelid ptosis, limitation of adduction or exotropia, the coexistence of ocular MG should be suspected. Appropriate ancillary testing should be performed to confirm the diagnosis and to guide optimal management.

Notes

Conflicts of interest

No potential conflict of interest relevant to this article was reported.

Funding

This work was supported by a clinical research grant from Pusan National University Hospital in 2022.

Author contributions

Conceptualization: HC, HJ. Data curation: JYL, HJ. Formal analysis: JYL. Funding acquisition: HC. Investigation: JYL, HJ. Methodology: HC, HJ. Resources: JYL, HJ. Software: JYL. Supervision: HC, HJ. Validation: HC, HJ. Visualization: JYL, HC, HJ. Writing-original draft: JYL. Writing-review & editing: HC, HJ. All authors have read and approved the final manuscript.

References

1. Mallika P, Tan A, Aziz S, Alwi SS, Chong M, Vanitha R, et al. Thyroid associated ophthalmopathy: a review. Malays Fam Physician 2009;4:8–14. 25606151.
2. Bartley GB, Fatourechi V, Kadrmas EF, Jacobsen SJ, Ilstrup DM, Garrity JA, et al. Clinical features of Graves' ophthalmopathy in an incidence cohort. Am J Ophthalmol 1996;121:284–90. 10.1016/s0002-9394(14)70276-4. 8597271.
3. Woo KI, Kim YD, Lee SY, ; Korean Society of Ophthalmic Plastic and Reconstructive Surgery. The clinical characteristics of thyroid orbitopathy in thyroid dysfunction patients in Korea. J Korean Ophthalmol Soc 2008;49:1387–96. 10.3341/jkos.2008.49.9.1387.
4. Engel AG, Tsujihata M, Lindstrom JM, Lennon VA. The motor end plate in myasthenia gravis and in experimental autoimmune myasthenia gravis: a quantitative ultrastructural study. Ann N Y Acad Sci 1976;274:60–79. 10.1111/j.1749-6632.1976.tb47676.x. 1066997.
5. Gunji K, Skolnick C, Bednarczuk T, Benes S, Ackrell BA, Cochran B, et al. Eye muscle antibodies in patients with ocular myasthenia gravis: possible mechanism for eye muscle inflammation in acetylcholine-receptor antibody-negative patients. Clin Immunol Immunopathol 1998;87:276–81. 10.1006/clin.1998.4536. 9646837.
6. Chung IY, Sheth SJ, Wells KK, Campbell TG. The usefulness of anti-acetylcholine receptor binding antibody testing in diagnosing ocular myasthenia gravis. J Neuroophthalmol 2021;41:e627–30. 10.1097/wno.0000000000001061. 32868574.
7. Claytor B, Li Y. Challenges in diagnosing coexisting ocular myasthenia gravis and thyroid eye disease. Muscle Nerve 2021;63:631–9. 10.1002/mus.27118. 33247453.
8. Vincent A, Palace J, Hilton-Jones D. Myasthenia gravis. Lancet 2001;357:2122–8. 10.1016/s0140-6736(00)05186-2. 11445126.
9. Benatar M. A systematic review of diagnostic studies in myasthenia gravis. Neuromuscul Disord 2006;16:459–67. 10.1016/j.nmd.2006.05.006. 16793269.
10. Lindstrom JM, Seybold ME, Lennon VA, Whittingham S, Duane DD. Antibody to acetylcholine receptor in myasthenia gravis: prevalence, clinical correlates, and diagnostic value. Neurology 1976;26:1054–9. 10.1212/wnl.26.11.1054. 988512.
11. Ludgate M, Swillens S, Mercken L, Vassart G. Homology between thyroglobulin and acetylcholinesterase: an explanation for pathogenesis of Graves’ ophthalmopathy? Lancet 1986;2:219–20. 10.1016/s0140-6736(86)92515-8. 2873461.
12. Sohn EJ, Hur MC, Ahn HB. The clinical features of ocular myasthenia gravis in thyroid-associated ophthalmopathy. J Korean Ophthalmol Soc 2014;55:325–32. 10.3341/jkos.2014.55.3.325.
13. Jacobson DM. Acetylcholine receptor antibodies in patients with Graves’ ophthalmopathy. J Neuroophthalmol 1995;15:166–70. 10.1097/00041327-199509000-00008. 8574362.
14. Kubiszewska J, Szyluk B, Szczudlik P, Bartoszewicz Z, Dutkiewicz M, Bielecki M, et al. Prevalence and impact of autoimmune thyroid disease on myasthenia gravis course. Brain and behavior 2016;6:e00537. 10.1002/brb3.537.
15. Chen CS, Lee AW, Miller NR, Lee AG. Double vision in a patient with thyroid disease: what’s the big deal? Surv Ophthalmol 2007;52:434–9. 10.1016/j.survophthal.2007.04.005. 17574067.
16. Marino M, Ricciardi R, Pinchera A, Barbesino G, Manetti L, Chiovato L, et al. Mild clinical expression of myasthenia gravis associated with autoimmune thyroid diseases. J Clin Endocrinol Metab 1997;82:438–43. 10.1210/jc.82.2.438. 9024233.
17. Kupersmith MJ, Fazzone HE. Comparing ocular muscle limitation tests for clinical trial use. Arch Ophthalmol 2004;122:347–8. 10.1001/archopht.122.3.347. 15006847.
18. Tran AQ, Zhou HW, Nanda T, Godfrey KJ, Tooley AA, North VS, et al. Evolution of asymmetric proptosis during the active phase of thyroid eye disease. Orbit 2023;42:251–5. 10.1080/01676830.2022.2088807. 35801656.
19. Kim IS, Choi JB, Rah SH, Lee SY. Classification of ptosis in Korea. J Korean Ophthalmol Soc 2005;46:1262–9.
20. Edmonson BC, Wulc AE. Ptosis evaluation and management. Otolaryngol Clin North Am 2005;38:921–46. 10.1016/j.otc.2005.08.012. 16214567.
21. Bartley GB, Gorman CA. Diagnostic criteria for Graves’ ophthalmopathy. Am J Ophthalmol 1995;119:792–5. 10.1016/s0002-9394(14)72787-4. 7785696.
22. Zoumalan CI, Lisman RD. Evaluation and management of unilateral ptosis and avoiding contralateral ptosis. Aesthet Surg J 2010;30:320–8. 10.1177/1090820x10374108. 20601555.
23. Lee JJ, Koh KM, Kim US. The anti-acetylcholine receptor antibody test in suspected ocular myasthenia gravis. J Ophthalmol 2014;2014:689792. 10.1155/2014/689792. 25478208.
24. Kupersmith MJ, Ying G. Ocular motor dysfunction and ptosis in ocular myasthenia gravis: effects of treatment. Br J Ophthalmol 2005;89:1330–4. 10.1136/bjo.2004.063404. 16170126.
25. Nicolle MW. Pseudo-myasthenia gravis and thymic hyperplasia in Graves’ disease. Can J Neurol Sci 1999;26:201–3. 10.1017/s0317167100000251. 10451743.
26. Weetman AP. Graves’ disease 1835-2002. Horm Res 2003;59 Suppl 1:114–8. 10.1159/000067837. 12638522.
27. Weinberg DA, Lesser RL, Vollmer TL. Ocular myasthenia: a protean disorder. Surv Ophthalmol 1994;39:169–210. 10.1016/0039-6257(94)90194-5. 7878520.
28. Bojikian KD, Francis CE. Thyroid eye disease and myasthenia gravis. Int Ophthalmol Clin 2019;59:113–24. 10.1097/iio.0000000000000277. 31233419.
29. Kusuhara T, Nakajima M, Imamura A. Ocular myasthenia gravis associated with euthyroid ophthalmopathy. Muscle Nerve 2003;28:764–6. 10.1002/mus.10471. 14639594.
30. Vargas ME, Warren FA, Kupersmith MJ. Exotropia as a sign of myasthenia gravis in dysthyroid ophthalmopathy. Br J Ophthalmol 1993;77:822–3. 10.1136/bjo.77.12.822. 8110684.
31. Zouvelou V, Potagas C, Karandreas N, Rentzos M, Papadopoulou M, Zis VP, et al. Concurrent presentation of ocular myasthenia and euthyroid Graves ophthalmopathy: a diagnostic challenge. J Clin Neurosci 2008;15:719–20. 10.1016/j.jocn.2007.09.028. 18424151.

Article information Continued

Table 1.

Characteristics of the patients

Characteristic Total patients (n=74) Seropositive (n=8) Seronegative (n=66) p-value
Age 49.9±16.7 43.8±20.8 50.6±16.1 0.321a)
Sex
 Male 31 (41.9) 3 (37.5) 28 (42.4) >0.999b)
 Female 43 (58.1) 5 (62.5) 38 (57.6)
Smoking history
 Yes 19 (25.7) 2 (25.0) 17 (25.8) >0.999b)
 No 55 (74.3) 6 (75.0) 49 (74.2)
Current thyroid status
 Hyperthyroid 31 (41.9) 4 (50.0) 27 (40.9) 0.678c)
 Hypothyroid 14 (18.9) 2 (25.0) 12 (18.2)
 Euthyroid 29 (39.2) 2 (25.0) 27 (40.9)
Prior steroid pulse therapy 4 (5.4) 0 (0.0) 4 (6.1) >0.999b)
Prior radiation therapy 0 (0.0) 0 (0.0) 0 (0.0) NA

Values are presented as mean±standard deviation or number (%).

NA, not applicable.

a)

Mann-Whitney U test.

b)

Fisher exact test.

c)

Pearson chi-square test.

Table 2.

Comparison of clinical features between seropositive and seronegative groups

Total patients Seropositive Seronegative p-value
Visual acuity (LogMAR)
 Right eye 0.06±0.10 0.06±0.09 0.06±0.10 0.847a)
 Left eye 0.08±0.15 0.06±0.11 0.08±0.16 0.960a)
Intraocular pressure (mmHg)
 Right eye 16.9±4.8 14.6±2.2 17.2±5.0 0.141a)
 Left eye 16.7±5.1 16.3±3.0 16.7±5.3 0.958a)
Asymmetric exophthalmosc) 18/65 (27.7) 1/7 (14.3) 17/58 (29.3) 0.663b)
Lid problem
 Lid retraction 22/74 (29.7) 0/8 (0.0) 22/66 (33.3) 0.096b)
 Lid lag 9/74 (12.2) 0/8 (0.0) 9/66 (13.6) 0.584b)
 Ptosis 15/74 (20.3) 4/8 (50.0) 11/66 (16.7) 0.048b)
Strabismus 47/74 (63.5) 7/8 (87.5) 40/66 (60.6) 0.245b)
 Vertical 38/74 (51.4) 6/8 (75.0) 32/66 (48.5) 0.263b)
 Exotropia 15/74 (20.3) 4/8 (50.0) 11/66 (16.7) 0.048b)
 Esotropia 15/74 (20.3) 1/8 (12.5) 14/66 (21.2) >0.999b)
 Vertical+horizontal 21/74 (28.4) 4/8 (50.0) 17/66 (25.8) 0.212b)
EOM limitation
 Supraduction 37/74 (50.0) 6/8 (75.0) 31/66 (47.0) 0.261b)
 Infraduction 11/74 (14.9) 2/8 (25.0) 9/66 (13.6) 0.339b)
 Adduction 11/74 (14.9) 4/8 (50.0) 7/66 (10.6) 0.014b)
 Abduction 18/74 (24.3) 2/8 (25.0) 16/66 (24.2) >0.999b)

Values are presented as mean±standard deviation or number (%).

LogMAR, logarithm of the minimum angle of resolution; EOM, extraocular movement.

a)

Mann-Whitney U test.

b)

Fisher exact test.

c)

Exophthalmos was evaluated with 65 patients.

p<0.05 was considered statistically significant.